| Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen | 1995/02/01 | English | 1,153 |
| Magnetic nanoparticles for drug delivery | 2006/01/01 | English | 612 |
| Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics | 2020/03/04 | English | 512 |
| Comparison of the proteolytic susceptibilities of homologous L‐amino acid, D‐amino acid, and N‐substituted glycine peptide and peptoid oligomers | 1995/05/01 | English | 340 |
| Ectonucleotidases: Some recent developments and a note on nomenclature | 2001/01/01 | English | 319 |
| Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor‐targeted drug delivery vectors | 2006/01/01 | English | 318 |
| The Role of miR‐21 in Cancer | 2015/06/16 | English | 233 |
| Integrin αvβ3‐targeted cancer therapy | 2008/09/01 | English | 231 |
| Anticonvulsant activity of (+)‐5‐methyl‐10, 11‐dihydro‐5H‐dibenzo[a, d]cyclohepten‐5, 10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties | 1982/01/01 | English | 226 |
| Mitogen‐inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs | 1992/01/01 | English | 215 |
| Dose translation between laboratory animals and human in preclinical and clinical phases of drug development | 2018/10/21 | English | 205 |
| Central sympathomimetic activity of (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo [a, d]cyclohepten‐5,10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties | 1982/01/01 | English | 203 |
| Network Pharmacology: A Rosetta Stone for Traditional Chinese Medicine | 2014/08/01 | English | 183 |
| Targeted nanoparticles for detecting and treating cancer | 2006/01/01 | English | 155 |
| Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies | 2004/03/01 | English | 145 |
| Biochemical, neurophysiological, and behavioral effects of Wy‐45,233 and other identified metabolites of the antidepressant venlafaxine | 1991/01/01 | English | 143 |
| Next‐generation antimalarial drugs: hybrid molecules as a new strategy in drug design | 2009/12/09 | English | 143 |
| Current drug targets for Alzheimer's disease treatment | 2002/07/01 | English | 140 |
| Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin‐S2 receptor blocker | 1986/05/01 | English | 139 |
| Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds | 2007/06/01 | English | 139 |
| Cyclodextrin complexes: Perspective from drug delivery and formulation | 2018/08/01 | English | 132 |
| 1,4‐Dihydropyridine Ca2+channel antagonists and activators: A comparison of binding characteristics with pharmacology | 1984/01/01 | English | 130 |
| Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems | 2019/05/29 | English | 125 |
| Biopolymer albumin for diagnosis and in drug delivery | 2003/03/01 | English | 123 |
| Viruses and their uses in nanotechnology | 2006/01/01 | English | 121 |
| Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects | 1988/01/01 | English | 120 |
| Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1 | 2001/08/01 | English | 118 |
| Amphiphilic block copolymer micelles for nanoscale drug delivery | 2006/01/01 | English | 116 |
| Natural products and colon cancer: current status and future prospects | 2008/11/01 | English | 116 |
| Restoration of shock‐suppressed behavior by treatment with (+)‐5‐methyl‐10,11‐dihydro‐5H‐dibenzo[a, d]cyclohepten‐5, 10‐imine (MK‐801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties | 1982/01/01 | English | 110 |